Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas M McCarty

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 12, 2022
Evaluating the state of the science for adeno-associated virus integration: An integrated perspectiveDenise E Sabatino, Frederic D Bushman, Randy J Chandler, et al.
Human Gene Therapy. Clinical Development|December 20, 2015
A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIBAaron S Meadows, F Jason Duncan, Marybeth Camboni, et al.
Human Gene Therapy. Clinical Development|April 12, 2014
Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primatesDarren A Murrey, Bartholomew J Naughton, F Jason Duncan, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 12, 2022
Evaluating the state of the science for adeno-associated virus integration: An integrated perspectiveDenise E Sabatino, Frederic D Bushman, Randy J Chandler, et al.
Human Gene Therapy. Clinical Development|December 20, 2015
A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIBAaron S Meadows, F Jason Duncan, Marybeth Camboni, et al.
Human Gene Therapy. Clinical Development|April 12, 2014
Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primatesDarren A Murrey, Bartholomew J Naughton, F Jason Duncan, et al.
Pageof 4